特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

EU5カ国におけるMA (メディカルアフェアーズ) 部門の評価:腎細胞癌

Medical Affairs Reputations: Renal Cell Carcinoma (EU5) 2018

発行 FirstWord 商品コード 497073
出版日 ページ情報 英文
納期: 即日から翌営業日
価格
詳細については [見積・お問合せ] ボタンよりお問い合わせ下さい。
EU5カ国におけるMA (メディカルアフェアーズ) 部門の評価:腎細胞癌 Medical Affairs Reputations: Renal Cell Carcinoma (EU5) 2018
出版日: 2018年03月01日 ページ情報: 英文
概要

当レポートでは、腎細胞癌治療薬の主要9製品を取り扱う各社メディカルアフェアーズ (MA) チームについてEU5カ国 (フランス・イタリア・ドイツ・スペイン・英国) の腫瘍専門医150名を対象に調査を行った結果から、各社チームのパフォーマンスおよび満足度に対するスコアリングおよびランキング、医師によるサービス利用の動向、要望、改善箇所などの分析をまとめています。

対象の企業・ブランド

  • Afinitor (エベロリムス:Novartis)
  • Avastin (ベバシズマブ:Roche)
  • Cabometyx (カボザンチニブ:Exelixis/Ipsen)
  • Inlyta (アキシチニブ:Pfizer)
  • Nexavar (ソラフェニブ:Bayer)
  • Opdivo (ニボルマブ:Bristol-Myers Squibb)
  • Sutent (スニチニブ:Pfizer)
  • Torisel (テムシロリムス:Pfizer)
  • Votrient (パゾパニブ:Novartis)

調査・分析内容の例

  • 医師のニーズ
    • 医師によるMAチームの利用方法・頻度
    • もっとも重要と考えるサービス
    • 最適なコンタクトの頻度と経路
  • MAチームの提供する内容
    • 医師によるチームとのインタラクションの印象
    • 医師によるチームのパフォーマンス・満足度ランキング:12項目
    • 他のチームとの比較
  • 改善が必要な箇所、など
目次

In the EU5, several of the renal cell carcinoma (RCC) medical affairs teams we surveyed are running neck and neck with at least one rival. The 150 medical oncologists we polled say that nearly every team needs improvement in two or more areas, but are those targeted improvements enough to put your team ahead of the competition?

Discover all the ways you can improve your medical affair services in Medical Affairs Reputations: Renal Cell Carcinoma (EU5). Comparing 10 major Renal Cell Carcinoma treatments from Novartis, Roche, Exelixis, Ipsen, Pfizer, Eisai, Bayer, and Bristol-Myers Squibb, this detailed report reveals:

  • How medical oncologists rate your team overall, and on 12 key medical affairs services
  • Which medical affairs services are most important
  • How, and how often medical oncologists want to meet with your team
  • What you can do to improve your medical affairs services

It's time to find out exactly how well your medical affairs team is performing against fierce competition - and establish an action plan to gain competitive advantage.

Top Takeaways

  • One team has the lead, but is it big enough? Rated for overall quality of interactions, the leading team is six points ahead of the team in 2nd place. Farther down the pack there are tight races for all other brands.
  • Modest performance. Overall, scores are hovering just above neutral, but the top teams earned somewhat positive scores-especially in the areas important to doctors.
  • Doctors rely on teams for a range of services. The most important medical affairs services relate to information provision, speaker programmes, and clinical trials.
  • Doctors want to see teams in-person and not too often. The report reveals how, and how frequently your team should engage.

Insight into Medical Affairs Teams for These Renal Cell Carcinoma Treatments

  • Afinitor (everolimus; Novartis)
  • Avastin (bevacizumab; Roche)
  • Cabometyx (cabozantinib; Exelixis/Ipsen)
  • Inlyta (axitinib; Pfizer)
  • Kisplyx (lenvatinib; Eisai)
  • Nexavar (sorafenib; Bayer)
  • Opdivo (nivolumab; Bristol-Myers Squibb)
  • Sutent (sunitinib; Pfizer)
  • Torisel (temsirolimus; Pfizer)
  • Votrient (pazopanib; Novartis)

An Expert-designed Competitive View of Your Medical Affairs Team

Developed with the help of medical affairs specialists, this report gives you an in-depth comparison of 10 medical affairs teams-answering important questions like:

What do doctors need?

  • How, and how often are they using your medical affairs team?
  • What services do they consider most important?
  • How often should you contact them? What channels are best?

Does your medical affairs team deliver?

  • How memorable are your team's interactions with doctors?
  • How do doctors rank your team for performance and satisfaction in 12 key areas?
  • How does your team compare to the competition-in each area, and overall?

What needs improvement?

  • Are you delivering the services that are most important to doctors?
  • Where do you need to improve?
  • How can your team enhance its services?

Based on Interviews with Practicing Doctors

We surveyed 150 medical oncologists from EU5 (France, Italy, Germany, Spain, UK) - chosen from the largest community of validated physicians in the world.

All respondents:

  • Have been practicing for between 3 and 35 years
  • See at least 5 patients a typical month
  • Devote at least 50% of their time to direct patient care
  • Have interacted with at least one listed product's medical affairs team in the past 6 months.

We conducted the survey between March 5-8, 2018.

Money Back Guarantee!

At FirstWord, we stand behind our reports. If you're not completely satisfied, we'll refund your money. Guaranteed.

Table of Contents

1. Objectives, Survey Methodology and Sampling, Products Included in the Survey, Executive Summary

2. Current Status of Interactions with Different Medical Affairs Teams

  • 2.2. Interactions in the past 6 months with Medical Affairs teams for each product
  • 2.3. Current frequency of interactions with medical affair teams for each product

3. Competitive Evaluation of Medical Affairs Teams Performance on Various Attributes

  • 3.2. Evaluation of overall quality of interactions with Medical Affairs teams for each product
  • 3.3. Attribute importance of Medical Affairs teams roles to physicians' practice
  • 3.4. EdgeMap analysis - Competitive evaluation on Medical Affairs teams performance on attributes
  • 3.5. Competitive evaluation of physicians satisfaction of interaction with Medical Affairs teams
  • 3.6. Need-Gap analysis by product

4. Preferred Interaction Media, Frequency, and Suggestions for Improvement

  • 4.1. Preferred interaction media and frequency, and suggestions for improvement

5. Appendix